XVARY Composite Score
63
/ 100
Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Solid Biosciences develops gene therapies for Duchenne muscular dystrophy and other rare muscle and heart diseases.
How it gets paid
Last year Solid Biosciences made n/a in revenue. Duchenne muscular dystrophy was the main engine at $0M, or 25% of sales.
What just happened
Solid’s last quarter showed -$0.48 EPS, with $0M revenue on a TTM basis.
At a Glance
B balance sheet — gets the job done, barely
60/100 earnings predictability — reasonably predictable
-$3.06 fy2024 eps est
$8M fy2022 rev est
1.0% operating margin
XVARY composite: 63/100 — average
What They Do
Solid Biosciences develops gene therapies for Duchenne muscular dystrophy and other rare muscle and heart diseases.
You are buying 4 pipeline shots, not a sales machine. That is the whole game here, because a $570M stock can rerate on one data set while revenue stays at $0M. SGT-001 is in Phase I/II, which means early human testing. Plain English: the company is still proving the drug works and stays safe.
How They Make Money
n/a
annual revenue
Duchenne muscular dystrophy
$0M
Cardiac programs
$0M
Friedreich's ataxia
$0M
Platform and licensing
$0M
The Products That Matter
Gene therapy for DMD
SGT-003
clinical-stage asset · $570M valuation tied to the readout
this is the only clinical-stage asset on the page, and its success or failure does most of the work behind the current $570M market value.
the main event
Preclinical cardiac gene therapy
SGT-601
late 2026 IND target
management plans an IND submission in late 2026, which makes this a real program but still a distant one compared with SGT-003.
future option
Non-product revenue stream
Collaboration Revenue
$8M · +18%
the company generated $8M here, up 18%, but that is still support revenue rather than proof of a commercial franchise.
not the thesis
Key Numbers
$570M
market cap
You are paying $570M for a company with $0M TTM revenue. That is a pipeline price, not a sales price.
$20M
long-term debt
Debt is only $20M, or 3% of capital. That limits leverage risk, not trial risk.
1.55
beta
A 1.55 beta means a 1% market move tends to become a 1.55% move here. You own extra volatility.
100
employees
100 employees is lean. That keeps the cost base small, but it also shows how early this business still is.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
- long-term debt $20M (3% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Solid’s last quarter showed -$0.48 EPS, with $0M revenue on a TTM basis.
The quarter was about pipeline spend, not customer demand. Revenue was still $0M, and the latest reported EPS loss was -$0.48.
$0M
revenue
-$0.48
eps
77.84%
revenue Vs. last year
the number that mattered
The -$0.48 EPS matters because there is no sales cushion behind it.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk here is clinical disappointment in SGT-003. This is not a diversified biotech page — one program carries most of a $570M market value.
Med
SGT-003 fails, and most of the story goes with it
The company is pre-commercial and SGT-003 is the only clinical-stage asset shown here. Negative safety or efficacy data would not trim the thesis — it would rewrite it.
Impact: this directly hits the asset supporting a $570M valuation.
Med
Runway risk does not disappear just because financing happened
The page shows a $120M cash balance and then a $240M oversubscribed financing in March 2026. That helps, but it also tells you the business still depends on external capital while product revenue remains at zero.
Impact: dilution can keep funding the science while still reducing your share of any eventual upside.
Med
Competition leaves little room for execution mistakes
The page points to a 5% estimated market share in 2026 against Sarepta. Even if the science works, Solid still has to earn relevance in a market where someone else already has scale.
Impact: the commercial win case can end up smaller than the clinical win case.
A weak readout from SGT-003 would hit the asset behind most of the $570M valuation. The March financing improves runway, but it does not turn a one-program biotech into a diversified business.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
The next SGT-003 update
March 2026 interim data supported a planned Q1 2026 trial start. The next clinical update is the event that can move this stock the most.
Financial
Cash after the $240M raise
The page shows $120M in cash and then a March 6, 2026 financing for $240M. You want clarity on how much runway that actually buys.
Competition
Whether the 5% share assumption still looks real
The current market-share assumption is modest, but it still depends on SGT-003 staying competitive with Sarepta. In a small market, a few data points can change the whole commercial picture.
Pipeline
SGT-601 late-2026 IND timing
SGT-601 is the only visible backup plan on the page. If that late-2026 IND slips, SLDB looks even more like a one-asset company.
Analyst Rankings
earnings predictability
60 / 100
in human-speak, analysts can model the losses directionally, but single-stock biotech events still create ugly surprises.
price stability
5 / 100
This stock does not trade like a steady operating business. It trades like a clinical headline waiting to happen.
Source: institutional data
Institutional Activity
institutional ownership data for SLDB is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$6
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive